Participants 242 333 3
in patients with metastatic breast cancer (MBC) who had previously received anthracyclines.
Participants 357 378 3
total of 210 patients
Participants 793 915 3
the 204 patients evaluable for response assessment, the response rates were 48.6% for GP1, 52.2% for GP2, and 52.3% for GD
Participants 1104 1141 3
the 208 patients evaluable for safety
